These payer-imposed policies — including prior authorization, step-therapy protocols and restrictive formularies — often restrict or deny specific therapies to patients due to cost, according to the report.
“[P]olicies that attempt to incentivize, force or coerce patients to accept anti-cancer therapy alternatives that are not recommended by their oncologist can threaten
both the outcomes for patients and the well-being of their families or caretakers,” the ASCO said.
In the statement, the ASCO reviews current management policies payers use to control the cost of cancer drugs and recommends ways to ensure these policies don’t undermine high-value patient care.
To view the full report, click here.
More articles on supply chain:
Global pharmerging market to reach $1.4B by 2025
FDA OKs Tecentriq for advanced bladder cancer
Bristol-Myers will license drugs to Biogen, Roche for $470M
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
